Abstract  by unknown
JACC Febmary1997
D l l d p d f
r ec D i r m c w
o s i h p ( 1 t
l l s v
4:15
[719-2] A P R
C
G T V C O S
A T S C C O R
B /
T i nu p m r
s m v a ( i w a
c p w s s i w q
t a n( f p s s
a q w a h t s d
d ( PW M A w p n
c l h p i ( + a t
c i m p c ( w t (
a s c p ( m f
u lt i d s p c (
i ns r p a 1 l (
r ( % d s ? f ( +
m U a a p s f
R ( (95%CI) p
Yes No
Y d 8 ( ( 0 ( N
C p 7 ( ( 1 ( N
T b 5 ( ( 1 ( N
T a 1 (5) 7 ( 0 ( N
I p o 6 ( ( 1 (
In stent protrudingatheroma 13 (66) 31 (44) 1,57 (1.05-2.35) 0.055
Odds r ( C l (
C oN a v t w $
a w a nr s c a H
t d i t r p p i s c
r w t e F t p c b c p
m t r m r f f
r e
m L F ‘ PR R D S
R L
S H E H H M N
P M R I nC e
U nE G
Itis u w i l o a s
s cp l e l i l d
d l ( 1 t a t p w ‘
i r h o s s e
o ‘ l p r m R t
s p c p w p r
l r s P ai b a
p ( T d h c f e t
g p P g ‘ P r
f r d s ( p e
d t a N p p
‘ sP r c f l r
b g w a R d > d
e f a q a C
d iM S ( N u
a m l d ( p i 6
m f R
‘Stent-like’ Stent group p value
post PTCA (n =98) (n= 137)
MLD (mm) pre-intewention 1.03 l 0.36 1.04 + 0.42 NS
MLD (mm) post-intervention 2.36 * 0,47 3.11 * 0 <
( f 1 * 0 2 l 0 <
R er ( 6 (
t ‘ sP r r l h s
i s M f c a I h a
s i t l r e
Imzl
A - Oral 77A
4:45
A E
R
F
B M F T J I . f C
B U U T A
r d f 1 d r
v e g f ( e v
e a s e S i e
i c v s m c p t
d h t s a s c r i
i f B i f P s i
t p e i a Z R
p p a p w a m
7 d f I a h (
u n ( m A w t r 1
d a C b c e r
v c = A w s d l M
a p 8 c s r f
l a i b t a
M i a r f 1 0 c 0
+ 0 V t s < 0 S m % c
s a n r 3 * 2 1 + 1
V t s < 0
C A e m I d
e g f r e r
i i f c m a a
d a s ( r s
5:00
17’19-51T R
U
M G M J P M H J L S
K K P A R D D
K D G M L W H C
W
T i r u w P m r
a u e l a ( r a
t ( f a P M e a
c t i r p i
u { m s l i h
= s – l a p p r
s p B s I s h s
t a r o t s a the t f
a s f l a t s i
D i r d a > s a o
a l R O m l a i
f k * < O a r a c
n t e ( a f +
+ m p < 0 a a e (
s a f + + m p < 0 N
I f l a 1 r l t p
s a < 0 f f I a <
p s a I T t t
c a w b f d i
r C C t i r
s i l a H t s r
l a a d i e i p
5:15
n7196 RI A Q
R
A L J P G M M J R R
R S S E G R N M
M L P T S C D U W
H C W
Q a ( s r f
f l d c w a s l a
s m r r r s t
s l e d f “ s
‘ e r r c p
r ‘ p t r n
7 ABSTRACTS – Oral JACC Febmary 1997
=41) and saphenous vein graft (N = 14) lesions using serial QCA methods
(CMS-GFT). Reference segments just proximal and distal to the gamma
proba margins were identified; the minimal lumen diameter (MLD) within
the axial stent length (“within stent”) and between the reference segments
(“within segment”) were uaed to determine residual and follow-up % stenoais.
QCA results are summarized (Table). tP <0.0001 vs. stent.
Reference,mm 2.83& 0.52 3.08+0.64 3.00+ 0.62
MLD,stentmm 1.o6+0.46 2.85& 0,73 2.12+ 0.88
segment 2.43+ 0.68t 1.72+ 0.69t
Stenosis,stent“A 61.9+ 16.4 5.6+22.5 28.0+ 29,10
segment 21.1l 14.5* 41,6+ 21.2t
rhe “within stent” restenosis rate was 25% and the “within segment”
restenosie rate was p We corrc/ude that the “within stent”
restenoeis rate is substantially lower than the “within segment” rate; and 2)
indices reflecting Iuminal changes within the entire coronaty segment may
provide a better angiographic surrogate for clinical restenosis.
u720 Advances in Defibrillatiordlmplantable
Antiarrhythmic Devices
Monday,March 17, 1997, 4:00 p.m.–5:3Op.m.
AnaheimMarriott,SouthHall
El7201 ArrhythmiaClaaaificationwiththe FiratDual-ChamberImplantableCardiovefterDefibrillator
W. Jung, B. Eemailzadeh 1, R. Nitzsche, C. Wolpert, B. Ludetftz for the
Defender 9001 Investigator Group. DepaHrnerrtof Cardiology, Urfiversityof
Bonn, Bonn, GermanH 1Department of Cardiovascular Surgery University
of Bonn, Bonn, Germany
Current implantable eerdioverter defibrillator (lCDs) usethetachycardia rate
with or without additional detection criteria such as rate stability and sudden
onaet for arrhythmia discrimination. The first dual-chamber ICD (Defender
9001, ELA Medical) uses a new arrhythmia detection algorithm based on
following criteria: rate, RR interval stability, atrioventricular (AV) relation
analyeis and atrial or ventricular acceleration in case of 1:1 AV relation. 42
patients with refractory ventricular tachyarrhyfhmias received the Defender
syetem.
Resuffa: During follow-up of 5.6 + 5.7 months (range of 1-16 months),
208 spontaneous arrhythmia episodes were recorded by the internal Helter
function and classified by the device as ventricular tachycerdia (VT, n =
87), ventricular fibrillation (VF, n = 52), or supreventricular origin (SVT, n
= 69). Helter data were reviewed by independent investigators who judged
the classification appropriate in all but 4 episodes. These 4 episodes were
classified by the device as VT, but were identified by the investigators as
atrial flutter with two to one conduction and a stable ventricular rate of
150 bpm. All eustained VT/VF apisodes were successfully terminated either
with antitechycerdia pacing or with the ficst shock therapy. Two non device
related deaths occurred. At the end of follow-up, arrhythmia detection was
programmed in a dual-chamber mode in 30 patients, in a monitor only mode
without VT therapy in 9 patients, and in a ventricular mode in 1 patient due
to an atrial lead dislodgement.
Cone/uaiona:l. Dual-chamber ICDsprovideaquivalent efficaW and safety
rates compared to single-chamber ICDS. 2. This new detection algorithm
significantly improves arrhythmia diagnosis accuracy. In a dual-chamber
ICD, this algorithm is highly effective in reducing the number of inappropriate
shocks without sacrifying the delivey of appropriate shocks,
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n7202 ComparativeSurvivalof MADIT-EligiblebutNoninduciblePatienta
J.P. Daubed, S.L. Higgins, W. Zareba, D.J. Wilber. The University of
Rocheater, RochesteL NY USA, University of Chicago, Chicago //, USA
We evaluated the survival of pts screened for MADIT (Multicenter Automatic
Defibrillator Implantation Trial) but found noninducible (Nl) at eledrophysiol-
ogy study, and therefore excluded from randomization. This group of NI pts
met all other MADIT eligibility criteria which included age 25-SO, prior Ml,
ejection fraction <0.343,and asymptomatic nonaustained VT (NSVT). All pts
screened at 3 MADITclinical centers who were NI (n =85) were followed until
MADIT termination (4/1/96). The NI group was compared (see Table below)
to the pts who were inducible, nonsuppressible and who were randomized to
mnventional (CONV) treatment in MADIT (amiodarone 74%, Class 1Aagent
11%).
GrOUD. N
8
1 9 N
+ + 0.035
F/Udays 592+ 399 755l 555 0.025
Totaldeaths 7 (8%) 39 (39”/.) <0.001
1yr K-Msurvival 98% 77% <0.001
By multivariate Cox model analysis risk of death was 4.24 times greater
for inducible status (CONV group) (confidence intervals 1.75-10.26, p =
0.001). Cone/usiona.’This study suggests that inducibiiity is associated with
significantly higher risk of death in pts with ejection fraction <0.36, NSVT
and prior ML
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720-3 EmpiricVerauaTeatedAntitschycardiaPacing:
ResultaFroma ProspectiveStudyIncluding2W
Patienta
A. Schaumann, F.von zur Muehlen, B.-D. Gonska, H. Kreuzer. University of
Goettingen, Dept of Cardiolog& Goeftingen, Germany
Antitachyeerdia pacing (ATP) is a programmable feature in impianteble car-
diovetier defibrillator (lCD). It was evaluated if ATP is effective for the
termination of ventricular tachycardias (VT) even if ATP could not be tested
at the predischarge examination for the successful termination of induced
VT.The results were compared to patients with tested ATP.
Of 200 patients after ICD implantation only 54 pts were inducible for
VT which could be terminated by ATP attempts at predischarge. In 146
patients ATP was programmed empirically although its efficacy could not
be tested due to non-inducible VT. The underlying heart diaeaae and left
ventricular function was comparable in both groups. ATP was programmed
as an autodecremental ramp with 61% of the tachycardia cycle length and
up to 3 sequences with 8 to 10 stimuli. Spontaneous VT during the follow-up
of 20.4 (S-55 months) rnontha were analyzed by the stored eieefrograms
and the therapy histoty recorded by the ICD. In the group of tested patients
95% of 34319spontaneous VT were terminated with ATP.ATP had no effect
on the tachycerdia in 2.4% and an acceleration was noted in 2.4% with
a ahock terminating the ventricular tachycerdia. Empirically programmed
ATP terminated 90% of 1346 spontaneous VT. The acceleration rate was
5%.
We conclude that empiric programmed ATP is highly effective (90%) in
terminating spontaneous ventricular tachycardias. The risk of acceleration is
still low (5%) even though it is higher when compared to tested ATP. ATP
should be programmed to all patients empirically regardless of pre-discharge
testing.
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-l ~he~~TR,~Automati~Atria,
DefibrillationSystem:ThreaholdStabilityandShock
Safety
W. Jung, P.G.Kirchhoff 1,’C.-P.LSU2,H.-F.Tse2, B. Li.ideritz for the Metrtx
System Clinical Investigational Group. Dept. of Cardiology University of
Bonn, Bonn, Germany,1Dept. of Cardiovascular Surgery University of
Bonn, Bonn, GermanK 2 University of Hong Kong, Hong Kong
Patients (pts) implanted with the Metrix 3000 Automatic Atrial Defibrillator
System were evaluated for chronic lead stability and shock safety. All pts
receivedthree leads at implant: an aetivefixation lead with a8cm defibrillation
coil in the tight atrium, a passive 6 cm defibrillation coil in the diatal coronary
sinus and a tined bipolar lead in the right ventricular apex. Lead stability
was assessed at pre-discharge, l-month and 3-months poet-implant. EDw
was measured using a modified up-down-up algorithm at implant and at
the 3-month follow-up visit. At these visits ahock safety was evaluated by
assessment of proarrhythmia post-shock and by telemetric marking of R-
waves. 15 pts with a age of 59 + 10 years received the METRIX system.
Results: The pts have been followed for a mean of 112 days (range
of 20-297). All pts underwent pre-discharge testing, and 6 pte had the 3-
month follow-up vieit. There was no early or late dielodgment of any lead.
Implant ED50was meaeured to be 196 + 46 V (1.4 * 0.7 J). Chronic (3-
month) EDWIwae measured to be 205 + 67 V (1.6 + 1.0 J). There was no
statistical difference between the acute and chronic ED50meaaurements. No
proarrhythmic events were obsetved from 1061 shocks (717 therapeutic and
384 induction) delivered to the pte.A total of 21,061 R-waveewere evaluated:
8,073 R-wavee were marked ae suitable for shock delivery of which 3,931
